Editorial |
| Qunibi WY. Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD J Am Soc Nephrol 2015 Mar;.
|
Electronic/Web Publication |
| Qunibi WY. Dialysis-related Amyloidosis 2017 Jan. |
| Qunibi WY. Prescribing and assessing adequate hemodialysis 2017 Jan. |
| Qunibi WY. Treatment of anemia in peritoneal dialysis patients 2017 Jan. |
| Qunibi WY. Overview of Chronic Kidney disease-Mineral Bone Disorder (CKD-MBD) 2017 Jan. |
| Qunibi WY. Protein intake in maintenance hemodialysis patients 2017 Jan. |
| Qunibi WY. Aluminum toxicity in end-stage renal disease 2017 Jan. |
| Qunibi WY. Hypertension following erythropoietin (EPO) in chronic kidney disease 2017 Jan. |
Journal Article |
| Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial Nephrol Dial Transplant 2013 Aug;.
|
Not Specified |
| Qunibi WY. Sodium Zirconium Cyclosilicate in Hyperkalemia N. Engl J Med. [Epub ahead of print]. N Engl J Med. 2015 Jan 15;372(3):222-31 2015 Jan;372(3):222-231.
|
| Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: The HARMONIZE Randomized Clinical Trial JAMA 2014 Dec;312(21):2223-2233.
|
Private |
| Funding Agency |
Nabi Pharmaceuticals |
| Title |
EPIC (Effect of PhosLo on Phosphorous Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Study of Calcium Acetate (PhosLo) on Phosphorous Levels in Subjects with Stage 4 Chronic Kid |
| Status |
Active |
| Period |
7/2005 - Present |
| Role |
Principal Investigator |
| Grant Detail |
|
| Funding Agency |
Luitpold Pharmaceuticals, Inc. |
| Title |
Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (VIT-45) versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease |
| Status |
Active |
| Period |
11/2005 - Present |
| Role |
Principal Investigator |
| Grant Detail |
|
| Funding Agency |
ZS Pharma |
| Title |
Phase III multicenter, two-phase, multi-dose, prospective, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of ZS(Microporous, Fractionated, Protonated Zirconium Silicate), and oral sorbent, in subjects with mild |
| Status |
Active |
| Period |
4/2013 - Present |
| Role |
Principal Investigator |
| Grant Detail |
|
